United States Anti-Doping Agency Reauthorization Act of 2020

To reauthorize the United States Anti-Doping Agency, and for other purposes. 1. Short title This Act may be cited as the United States Anti-Doping Agency Reauthorization Act of 2020 2. Findings Congress makes the following findings: (1) The United States Anti-Doping Agency— (A) is the independent national anti-doping organization of the United States; and (B) manages the anti-doping program, results management processes, drug reference resources, and athlete education for all United States Olympic Committee-recognized national governing bodies and the athletes and events of such national governing bodies. (2) The United States Anti-Doping Agency contributes to the advancement of clean sport through scientific research, anti-doping education, and outreach programs, and the mission of the United States Anti-Doping Agency is to preserve the integrity of competition and protect the rights of athletes. (3) Participation in youth sports has the potential to equip young athletes with important skills and values necessary for success in life, and it is essential that the culture of youth sports emphasizes such skills and values. (4) The TrueSport program of the United States Anti-Doping Agency partners with youth sport organizations across the United States to promote sportsmanship, character building, and healthy performance through the use of targeted educational materials designed to promote a positive youth sport experience. (5) In modifying the authority of the United States Anti-Doping Agency to include the promotion of the positive values of youth sport, Congress sends a strong signal that the goals of youth sport should include instilling in young athletes the values of integrity, respect, teamwork, courage, and responsibility. (6) Due to the unique leadership position of the United States in the global community, adequate funding of the anti-doping and clean sport programs of the United States Anti-Doping Agency is imperative to the preparation for the 2028 Summer Olympic Games, which will be held in Los Angeles, California. (7) Increased appropriations for fiscal years 2021 through 2029 would enable the United States Anti-Doping Agency to directly affect the integrity and well-being of sport, both domestically and internationally. 3. Promotion of youth sports Section 701(b) of the Office of National Drug Control Policy Reauthorization Act of 2006 ( 21 U.S.C. 2001(b) (1) in paragraph (4), by striking the period at the end and inserting ; and (2) by adding at the end the following: (5) promote a positive youth sport experience by using a portion of the funding of the United States Anti-Doping Agency to provide educational by providing educational . 4. Authorization of appropriations Section 703 of the Office of National Drug Control Policy Reauthorization Act of 2006 ( 21 U.S.C. 2003 703. Authorization of appropriations There are authorized to be appropriated to the United States Anti-Doping Agency— (1) for fiscal year 2021, $15,500,000; (2) for fiscal year 2022, $16,200,000; (3) for fiscal year 2023, $16,900,000; (4) for fiscal year 2024, $17,700,000; (5) for fiscal year 2025, $18,500,000; (6) for fiscal year 2026, $19,800,000; (7) for fiscal year 2027, $22,100,000; (8) for fiscal year 2028, $24,900,000; and (9) for fiscal year 2029, $23,700,000. . 5. Information sharing Except as otherwise prohibited by law and except in cases in which the integrity of a criminal investigation would be affected, pursuant to the obligation of the United States under Article 7 of the United Nations Educational, Scientific, and Cultural Organization International Convention Against Doping in Sport done at Paris October 19, 2005, and ratified by the United States in 2008, the Attorney General, the Secretary of Homeland Security, and the Commissioner of Food and Drugs shall provide to the United States Anti-Doping Agency any relevant information relating to the prevention of the use of performance-enhancing drugs or the prohibition of performance-enhancing methods. 6. Report on capacity to implement equine anti-doping and medication control program Not later than 180 days after the date of the enactment of this Act, the United States Anti-Doping Agency shall submit to Congress a report that— (1) assesses the capacity of the United States Anti-Doping Agency to implement an equine anti-doping and medication control program; and (2) includes— (A) recommendations with respect to best practices for design, resources, and any other consideration necessary for the successful implementation of such a program in the United States; and (B) recommendations developed in consultation with the National Veterinary Services Laboratories with respect to the appropriate technical standards and best practices for such a program. November 17, 2020 Reported with amendments

Summary: United States Anti-Doping Agency Reauthorization Act of 2020 This bill authorizes appropriations for the U.S. Anti-Doping Agency (USADA) through FY2029. USADA shall serve as the independent anti-doping organization for the amateur athletic competitions recognized by the U.S. Olympic and Paralympic Committee, be responsible for certifying in advance any testing conducted by international organizations under the World Anti-Doping Code for international amateur athletes and athletic competitions occurring within U.S. jurisdiction, and be recognized worldwide as the independent national anti-doping organization for the United States. Any administrative action taken by USADA to enforce a USADA policy, procedure, or requirement against a person with respect to a violation of federal law shall be carried out in a manner that provides due process protection to the person. The bill also directs (1) USADA to promote a positive youth sport experience by providing educational materials on sportsmanship, character building, and healthy performance for those participating in youth sports; and (2) the Department of Justice, the Department of Homeland Security, and the Food and Drug Administration to provide to USADA information relating to the prevention of the use of performance-enhancing drugs or the prohibition of performance-enhancing methods.